In this 30-minute webinar, Dr. James Lugo, Chief Scientific officer for Lonza presents the clinical research behind UC-II® which is the basis for the claims they make about this ingredient. He also addresses the mechanism of action and how the studies compare to glucosamine.
James Lugo, Ph.D
As Chief Scientific officer for Lonza, Dr. James Lugo oversees R&D activities for Lonza’s Consumer Health & Nutrition Business Unit. He has more than 20 years of marketing and business development experience in the pharmaceutical industry. His expertise includes product development from concept through launch, new business development, clinical trial design and management, medical marketing, thought leader board management, as well as brand and general marketing management.
During his 7 year tenure at InterHealth, now Lonza, Dr. Lugo has overseen and participated in the publication of 9 peer-reviewed scientific papers, including the first clinical study carried out in healthy subjects for joint health.
Dr. Lugo has a bachelor’s degree in Chemistry from Brooklyn College, a Ph.D. in Immunology from MIT, and an MBA from the University of California (Los Angeles). Dr. Lugo was a Jane Coffin Childs Fellow at Caltech.